<DOC>
	<DOCNO>NCT00952588</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability AZD1152 alone combination low dose cytosine arabinoside ( LDAC ) comparison LDAC alone AML patient .</brief_summary>
	<brief_title>Study Investigate Efficacy , Safety Tolerability AZD1152 Alone Combination With Low Dose Cytosine Arabinoside ( LDAC ) Acute Myeloid Leukaemia ( AML ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Provision write informed consent Newly diagnose male female patient age 60 De Novo Secondary AML Not eligible intensive induction anthracyclinebased combination chemotherapy result least one following : Age â‰¥75 year ; Adverse cytogenetics , e.g. , define MRC Prognostic Groupings ; WHO performance status &gt; 2 ; Organ dysfunction arise significant comorbidities directly link leukaemia Participation another clinical study investigational product receive within 14 day first dose study , time patient recover sideeffects associate investigational product Administration LDAC clinically contraindicate Patients AML FAB M3 classification Acute Promyelocytic Leukaemia ( APL ) Patients blast crisis chronic myeloid leukaemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Acute Myeloid Leukaemia ,</keyword>
	<keyword>AML</keyword>
</DOC>